Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rebecca Gilley

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Cell Cycle (Georgetown, Tex.)|March 10, 2016
Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferationPamela A Lochhead, Jonathan Clark, Lan-Zhen Wang, et al.
Bioconjugate Chemistry|April 29, 2017
Visualization of Endogenous ERK1/2 in Cells with a Bioorthogonal Covalent ProbeJames Sipthorp, Honorine Lebraud, Rebecca Gilley, et al.
Nature Communications|November 17, 2025
RAF inhibitors activate the integrated stress response by direct activation of GCN2Rebecca Gilley, Andrew M Kidger, Graham Neill, et al.
Nature Communications|May 4, 2019
MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAF<sup>V600E</sup> amplification whereas KRAS<sup>G13D</sup> amplification promotes EMT-chemoresistanceMatthew J Sale, Kathryn Balmanno, Jayeta Saxena, et al.
Nature Communications|November 16, 2019
Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitorsMatthew J Sale, Emma Minihane, Noel R Monks, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Cell Cycle (Georgetown, Tex.)|March 10, 2016
Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferationPamela A Lochhead, Jonathan Clark, Lan-Zhen Wang, et al.
Bioconjugate Chemistry|April 29, 2017
Visualization of Endogenous ERK1/2 in Cells with a Bioorthogonal Covalent ProbeJames Sipthorp, Honorine Lebraud, Rebecca Gilley, et al.
Nature Communications|November 17, 2025
RAF inhibitors activate the integrated stress response by direct activation of GCN2Rebecca Gilley, Andrew M Kidger, Graham Neill, et al.
Nature Communications|May 4, 2019
MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAF<sup>V600E</sup> amplification whereas KRAS<sup>G13D</sup> amplification promotes EMT-chemoresistanceMatthew J Sale, Kathryn Balmanno, Jayeta Saxena, et al.
Nature Communications|November 16, 2019
Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitorsMatthew J Sale, Emma Minihane, Noel R Monks, et al.
Pageof 2